Zevra Therapeutics, Inc. Common Stock (ZVRA) Stock Price

ZVRAStock

$9.94−12.65%52W

Market Cap$590.27M

P/E7.30x

PEG Ratio10.67

Div yield—

Beta0.98

ZVRA Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-8.37%

Price vs S&P 500 (4W)-13.50%

PEG Ratio10.67

VGM Score57.30

P/E Ratio (Annual)7.30x

Book Value / Share (Quarterly)$3.67

P/TBV (Annual)3.40x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)116.72%

Cash Flow / Share (Quarterly)$0.55

Price vs S&P 500 (YTD)-0.99%

Gross Margin (TTM)99.07%

Net Profit Margin (TTM)42.82%

EPS (TTM)$0.97

10-Day Avg Trading Volume0.82M

EPS Excl Extra (TTM)$0.97

Revenue Growth (5Y)51.61%

EPS (Annual)$1.45

ROI (Annual)38.43%

Gross Margin (Annual)96.37%

Net Profit Margin (5Y Avg)-192.68%

Cash / Share (Quarterly)$3.73

P/E Basic Excl Extra (TTM)10.43x

Revenue Growth QoQ (YoY)53.25%

P/E Normalized (Annual)7.30x

ROA (Last FY)29.23%

Revenue Growth TTM (YoY)119.40%

EBITD / Share (TTM)$1.42

ROE (5Y Avg)-68.35%

Operating Margin (TTM)60.54%

Cash Flow / Share (Annual)$-0.04

P/B Ratio2.79x

P/B Ratio (Quarterly)3.89x

Net Income / Employee (Annual)$1,364,400

EV / Revenue (TTM)3.40x

Net Interest Coverage (TTM)99.27x

ROA (TTM)20.51%

EPS Growth QoQ (YoY)-89.24%

EV / EBITDA (TTM)5.52x

EPS Incl Extra (Annual)$1.45

Current Ratio (Annual)5.68x

Quick Ratio (Quarterly)5.02x

3-Month Avg Trading Volume1.21M

52-Week Price Return-12.65%

P/E Incl Extra (TTM)10.43x

Revenue / Employee (TTM)$2,230,700

Tangible BV / Share (Quarterly)$3.57

P/S Ratio (Annual)5.71x

Asset Turnover (Annual)0.37x

52-Week High$15.04

Operating Margin (5Y Avg)-208.77%

EPS Excl Extra (Annual)$1.45

CapEx CAGR (5Y)94.50%

26-Week Price Return1.53%

Quick Ratio (Annual)5.46x

13-Week Price Return-22.16%

Total Debt / Equity (Annual)0.40x

Current Ratio (Quarterly)5.17x

Enterprise Value$462.59M

Revenue / Share Growth (5Y)-11.05%

Asset Turnover (TTM)0.48x

Revenue / Employee (Annual)$1,745,400

Pretax Margin (Annual)81.41%

Cash / Share (Annual)$3.36

3-Month Return Std Dev69.68%

Net Income / Employee (TTM)$955,100

EBITDA Interim CAGR (5Y)20.70%

ROE (Last FY)53.82%

Net Interest Coverage (Annual)10.98x

EPS Basic Excl Extra (Annual)$1.45

P/FCF (TTM)18.63x

Receivables Turnover (TTM)6.68x

EV / Free Cash Flow (TTM)14.18x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$0.97

Receivables Turnover (Annual)6.49x

ROI (TTM)27.93%

P/S Ratio (TTM)4.47x

Pretax Margin (5Y Avg)-180.49%

Revenue / Share (Annual)$1.86

Tangible BV / Share (Annual)$2.61

Forward P/E12.07x

Price vs S&P 500 (52W)-28.19%

P/E Ratio (TTM)10.43x

Year-to-Date Return10.94%

5-Day Price Return-12.19%

EPS Normalized (Annual)$1.45

ROA (5Y Avg)-19.83%

Net Profit Margin (Annual)78.17%

Month-to-Date Return-9.39%

Cash Flow / Share (TTM)$-1.15

EBITD / Share (Annual)$-1.03

Operating Margin (Annual)-59.12%

LT Debt / Equity (Annual)0.40x

P/CF (TTM)18.20x

ROI (5Y Avg)-31.78%

P/E Excl Extra (TTM)10.43x

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$0.97

P/TBV (Quarterly)4.00x

P/B Ratio (Annual)3.26x

Inventory Turnover (TTM)0.71x

Pretax Margin (TTM)50.92%

Book Value / Share (Annual)$2.72

Price vs S&P 500 (13W)-24.85%

Beta0.98x

P/FCF (Annual)58.79x

Revenue / Share (TTM)$2.22

ROE (TTM)32.77%

52-Week Low$8.01

vGradeC

gGradeB

mGradeC

vgmGradeC

ZVRA Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	$0.18	$0.25	+41.51%(+$0.07)
Q1 2026	May 6, 2026	$0.08	$0.18	+114.93%(+$0.10)
Q4 2025	Mar 9, 2026	$0.04	$0.19	+322.22%(+$0.15)
Q3 2025	Nov 5, 2025	-$0.02	-$0.01	+50.00%(+$0.01)
Q2 2025	Aug 12, 2025	$1.38	-$0.06	-104.34%(-$1.44)

ZVRA Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.27

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ZVRAZevra Therapeutics, Inc. Common Stock	C	B	C	4.5x	119.4%	99.1%	—	$9.94
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Zevra Therapeutics, Inc. Common Stock

Zevra Therapeutics is a biopharmaceutical company focused on developing and commercializing transformational therapies for rare diseases with limited or no existing treatment options. The company employs data-driven strategies to overcome complex drug development challenges and accelerate the delivery of novel therapeutics to underserved patient populations.